Article: Serum MBP immunoreactivity and immunoglobulin level as markers of tumour type

Forty three patients, admitted to the department of Neurological Surgery for management of central nervous system tumours, were studied pre-operatively for serum myelin basic protein immunoreactivity as a marker of central nervous system lesion and for circulating immunoglobulins and complement (C3) levels. Myelin basic protein concentration did not appear to correlate with tumour type or grade. Serum immunoglobulin levels were found to be within the normal range but the mean IgM level was significantly higher in the glioma group when compared with meningiomas.

Citing Articles

Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL.

Li B, Zhang G, Li C, Li R, Lu J, He Z Oncotarget. 2017; 8(39):64984-64998.

PMID: 29029406 PMC: 5630306. DOI: 10.18632/oncotarget.11401.

References

1.

Hekim N, Sayin E, Demirkaya E, BERKAY F . Serum IgM level as an index of malignancy in brain tumours. Acta Neurochir (Wien). 1981; 59(3-4):227-30. DOI: 10.1007/BF01406352. View

2.

MAHALEY Jr M, Brooks W, Roszman T, Bigner D, Dudka L, Richardson S . Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg. 1977; 46(4):467-76. DOI: 10.3171/jns.1977.46.4.0467. View

3.

Garson J, Quindlen E, KORNBLITH P . Identification of immunoglobulin classes responsible for humoral immunity to human gliomas. Surg Forum. 1979; 30:461-3. View

4.

Kung P, Lee J, Bakay L . Vascular invasion by glioma cells in man: an electron microscopic study. J Neurosurg. 1969; 31(3):339-45. DOI: 10.3171/jns.1969.31.3.0339. View

5.

KORNBLITH P, DOHAN Jr F, Wood W, Whitman B . Human astrocytoma: serum-mediated immunologic response. Cancer. 1974; 33(6):1512-9. DOI: 10.1002/1097-0142(197406)33:6<1512::aid-cncr2820330607>3.0.co;2-t. View

6.

Thomas D, Palfreyman J, Ratcliffe J . Serum-myelin-basic-protein assay in diagnosis and prognosis of patients with head injury. Lancet. 1978; 1(8056):113-5. DOI: 10.1016/s0140-6736(78)90415-4. View

7.

Tabuchi K, Kawakami Y, Nishimoto A . Immunohistochemical demonstration of IgG in meningioma. Acta Neurochir (Wien). 1981; 55(3-4):201-11. DOI: 10.1007/BF01808437. View

8.

TOKUMARU T, Catalano L . Elevation of serum immunoglobulin M (IgM) level in patients with brain tumors. Surg Neurol. 1975; 4(1):17-21. View

9.

Budka H . Hyaline inclusions (Pseudopsammoma bodies) in meningiomas: immunocytochemical demonstration of epithel-like secretion of secretory component and immunoglobulins A and M. Acta Neuropathol. 1982; 56(4):294-8. DOI: 10.1007/BF00691261. View

10.

Phillips J, Sujatanond M, Martuza R, Quindlen E, Wood W, KORNBLITH P . Cytotoxic antibodies in preoperative glioma patients: a diagnostic assay. Acta Neurochir (Wien). 1976; 35(1-3):43-52. DOI: 10.1007/BF01405931. View

11.

Cohen S, McKhann G, Guarnieri M . A radioimmunoassay for myelin basic protein and its use for quantitative measurements. J Neurochem. 1975; 25(4):371-6. DOI: 10.1111/j.1471-4159.1975.tb04329.x. View

12.

Palfreyman J, Johnston R, Ratcliffe J, Thomas D, Forbes C . Radioimmunoassay of serum myelin basic protein and its application to patients with cerebrovascular accident. Clin Chim Acta. 1979; 92(3):403-9. DOI: 10.1016/0009-8981(79)90220-1. View

Serum MBP Immunoreactivity and Immunoglobulin Level As Markers of Tumour Type